RXST Stock Forecast: RxSight, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering RxSight, Inc. hold a median 12-month price target of $6 — +34.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 54 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores RxSight, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (12): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RXST stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RXST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +34.5% from it.
Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Nov 2026 | Needham | Maintains | Buy | $11 → $7.00 |
| 4 Nov 2026 | Piper Sandler | Maintains | Neutral | $10 → $8.00 |
| 4 Nov 2026 | Wells Fargo | Maintains | Equal-Weight | $9.00 → $6.00 |
| 22 Sept 2026 | B of A Securities | Maintains | Underperform | $6.50 → $5.50 |
| 22 Sept 2026 | Jefferies | Maintains | Hold | $6.50 → $5.75 |
| 10 Aug 2026 | Stifel | Maintains | Hold | $8.00 → $7.00 |
| 6 Aug 2026 | UBS | Maintains | Neutral | $5.50 → $6.30 |
| 28 July 2026 | UBS | Assumes | Neutral | $9.00 → $5.50 |
| 7 July 2026 | B of A Securities | Maintains | Underperform | $8.00 → $6.50 |
| 7 July 2026 | Needham | Reiterates | Buy | $11 |
| 7 May 2026 | Needham | Maintains | Buy | — |
| 7 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 Mar 2026 | Stifel | Maintains | Hold | — |
| 26 Feb 2026 | Needham | Reiterates | Buy | — |
| 26 Feb 2026 | Piper Sandler | Maintains | Neutral | — |
| 26 Feb 2026 | UBS | Maintains | Neutral | — |
| 20 Jan 2026 | Piper Sandler | Maintains | Neutral | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 Nov 2025 | JP Morgan | Maintains | Underweight | — |
| 6 Nov 2025 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RXST.
This page is one stock. Monday covers all of them.
RXST appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RXST vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, RxSight, Inc. returned −50.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RXST analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.6×
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 55% of US stocks
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 76.7%
- Operating margin
- −50.4%
- Net margin
- —
Higher than 88% of US stocks
Higher than 18% of US stocks
- Return on equity
- −20.1%
- Return on assets
- −11.8%
- Dividend yield
- —
Higher than 32% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
RxSight, Inc. has a market value of $193.3M.
Revenue in the twelve months to 30 June 2026: $127.6M. The latest quarter grew 0.3% year on year.
Net income over the same four quarters: −$46.9M, a −36.8% net margin.
Diluted earnings per share, trailing twelve months: −$1.13.
Free cash flow in the twelve months to 30 June 2026: −$27.2M.
RxSight, Inc. employs 461 people — $277K of revenue per employee.
Data provided by Twelve Data
RXST and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RXST’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own RxSight, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RXST
What is the RXST stock price forecast for 2026-2027?
The 10 Wall Street analysts covering RxSight, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RXST stock a buy right now?
Of the 10 analysts covering RxSight, Inc., 1 rate it a Buy, 7 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks RxSight, Inc. 54 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RXST?
As at 21 Nov 2026, RxSight, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).
Will RXST stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +34.5% from the last close, and Ticker Nerd's factor model ranks RxSight, Inc. 54 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RXST stock forecast for 2030?
No analyst covering RxSight, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RXST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.
How has RXST stock performed over the past year?
RxSight, Inc. returned -50.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does RxSight, Inc. do?
RxSight, Inc. is a commercial-stage ophthalmic medical technology company focused on improving vision outcomes after cataract surgery. The company’s core offering is the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens and the Light Delivery Device, along with related accessories used by eye care professionals.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage ophthalmic medical technology company focused on improving vision outcomes after cataract surgery. The company’s core offering is the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens and the Light Delivery Device, along with related accessories used by eye care professionals. This platform allows doctors to customize and optimize a patient’s visual acuity after implantation, addressing a major need in premium cataract care. RxSight serves ophthalmic surgeons, ambulatory surgery centers, and ophthalmology practices, with its products used in the U.S. cataract surgery market and selected international markets through distribution partners. Headquartered in Aliso Viejo, California, RxSight operates as a specialized medical device business centered on adjustable intraocular lens technology and post-surgical vision refinement.
CEO Mr. Aziz Mottiwala M.B.A. · 461 employees · United States · https://rxsight.com